Investing.com -- Acrivon Therapeutics Inc (NASDAQ:ACRV) stock plummeted 29.2% Thursday after the clinical-stage biotech company released mixed results from its ongoing cancer treatment trials.

A study led by researchers at Moffitt Cancer Center found that normal cells surrounding a tumor, known as cancer-associated ...

Cancer natives experience a period of contrasts, where early confusion gives way to creative opportunities and renewed ...

A randomized trial from Vanderbilt-Ingram Cancer Center reveals that magnesium may be the missing key to keeping vitamin D ...

Olympian Ciara Mageean has shared a major health update after revealing that she was diagnosed with cancer last year. The ...

New research examining 62 studies finds alcohol linked to breast, colorectal, and liver cancer. Learn what tens of millions ...

In the January 9 episode of Beyond the Gates, Anita began her chemotherapy, while Nicole and Dani learned if they carried the ...

Know what the year 2026 holds for Cancer natives. Explore Vedic predictions on career, business, health, love life, finances, ...

Cancer Horoscope 2026 brings mixed results with growth, lessons, financial gains, emotional challenges, career progress, and ...

Hawaiʻi is landing some serious hits in the fight against cancer, even if it is still running lean on the money side. A new ...